ArticleFrontiers in immunology2026
Development and validation of a predictive nomogram for response to biologics and targeted therapy in Crohn's disease: a retrospective cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biologics and targeted therapies are a first-line treatment option for individuals with Crohn's disease (CD). Nevertheless, clinical remission rates vary considerably among different biologics and targeted therapies. This study aims to develop and validate a predictive nomogram for the response to biologics and targeted therapy in individuals with CD. Methods: This study included individuals with CD admitted to the First People's Hospital of Wuhu from January 2020 to June 2025. Clinical remission rates at 14 and 26 weeks were observed. The clinical remission rates of different biologics and targeted therapy were analyzed using the chi-square test, and multiple comparisons were performed. The least absolute contraction and selection operator (LASSO) regression algorithm was used to determine variables related to clinical remission. A nomogram model was constructed, and the model performance was assessed utilizing receiver operating characteristic (ROC) curves, calibration curves, and decision curves (DCA). Internal validation was performed using repeated sampling and Harrell's concordance index (C-index). Results: 218 patients were included in the study. Compared with other biologics, upadacitinib (UPA) had the highest clinical remission rate at week 26 (94.1%,16/17subjects). Nine variables were identified by LASSO regression, including pre-treatment Crohn's disease activity index (CDAI), disease duration, smoking history, disease site, disease behavior, perianal lesions, hemoglobin (Hb), erythrocyte sedimentation rate (ESR), and type of biologic. The area under the curve (AUC value) was 0.796. The calibration curve and DCA curve showed good calibration and clinical applicability. The internal validation also demonstrated moderate discriminative performance, with a C-index of 0.74. Conclusions: The study results demonstrate that UPA appears to show a significant clinical remission rate in a small cohort, but this finding needs to be validated in a larger-scale study. Furthermore, a practical tool has been developed to help clinicians identify the treatment response to biologics and targeted therapy in CD patients, promoting the development of personalized treatment and precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.